
Gene Fusion Testing Market by Technique (Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring), Indication (Haematological Malignacies, Solid Tumors), Application, End User - Global Forecast 2024-2030
Description
Gene Fusion Testing Market by Technique (Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring), Indication (Haematological Malignacies, Solid Tumors), Application, End User - Global Forecast 2024-2030
The Gene Fusion Testing Market size was estimated at USD 428.34 million in 2023 and expected to reach USD 480.95 million in 2024, at a CAGR 12.40% to reach USD 971.34 million by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Gene Fusion Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gene Fusion Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Gene Fusion Testing Market, highlighting leading vendors and their innovative profiles. These include Amoy Diagnostics Co., Ltd., Arima Genomics, Inc., Biocare Medical, LLC, Biocartis NV, Caris Life Sciences, Danaher Corporation, Empire Genomics, Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., OncoDNA SA, Paragon Genomics, Inc., QIAGEN N.V., Quest Diagnostics Incorporated., SOPHiA GENETICS SA, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Gene Fusion Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
Technique
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Nanostring
NGS Amplicon
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Indication
Haematological Malignacies
Solid Tumors
Application
Disease Diagnosis
Research
End User
Academic & Research Centers
Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Gene Fusion Testing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gene Fusion Testing Market?
3. What are the technology trends and regulatory frameworks in the Gene Fusion Testing Market?
4. What is the market share of the leading vendors in the Gene Fusion Testing Market?
5. Which modes and strategic moves are suitable for entering the Gene Fusion Testing Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Gene Fusion Testing Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of cancer worldwide
- 5.1.1.2. Increasing genomic and molecular biology reserach
- 5.1.1.3. Extensive use for discovery of biomarkers
- 5.1.2. Restraints
- 5.1.2.1. High cost and limited accessibility to gene fusion testing
- 5.1.3. Opportunities
- 5.1.3.1. Advent of liquid-biopsy based gene fusion testing technologies
- 5.1.3.2. Inclination towards personalize medicine and targeted therapies
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulations and dearth of skilled professionals
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Gene Fusion Testing Market, by Technique
- 6.1. Introduction
- 6.2. Fluorescence In Situ Hybridization (FISH)
- 6.3. Immunohistochemistry (IHC)
- 6.4. Nanostring
- 6.5. NGS Amplicon
- 6.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
- 7. Gene Fusion Testing Market, by Indication
- 7.1. Introduction
- 7.2. Haematological Malignacies
- 7.3. Solid Tumors
- 8. Gene Fusion Testing Market, by Application
- 8.1. Introduction
- 8.2. Disease Diagnosis
- 8.3. Research
- 9. Gene Fusion Testing Market, by End User
- 9.1. Introduction
- 9.2. Academic & Research Centers
- 9.3. Hospitals & Diagnostic Laboratories
- 9.4. Pharmaceutical & Biotechnology Companies
- 10. Americas Gene Fusion Testing Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Gene Fusion Testing Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Gene Fusion Testing Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Amoy Diagnostics Co., Ltd.
- 14.1.2. Arima Genomics, Inc.
- 14.1.3. Biocare Medical, LLC
- 14.1.4. Biocartis NV
- 14.1.5. Caris Life Sciences
- 14.1.6. Danaher Corporation
- 14.1.7. Empire Genomics, Inc.
- 14.1.8. F. Hoffmann-La Roche Ltd.
- 14.1.9. Guardant Health, Inc.
- 14.1.10. Illumina, Inc.
- 14.1.11. Integrated DNA Technologies, Inc.
- 14.1.12. Myriad Genetics, Inc.
- 14.1.13. Natera, Inc.
- 14.1.14. NeoGenomics, Inc.
- 14.1.15. OncoDNA SA
- 14.1.16. Paragon Genomics, Inc.
- 14.1.17. QIAGEN N.V.
- 14.1.18. Quest Diagnostics Incorporated.
- 14.1.19. SOPHiA GENETICS SA
- 14.1.20. Thermo Fisher Scientific Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. GENE FUSION TESTING MARKET RESEARCH PROCESS
- FIGURE 2. GENE FUSION TESTING MARKET SIZE, 2023 VS 2030
- FIGURE 3. GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GENE FUSION TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. GENE FUSION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GENE FUSION TESTING MARKET DYNAMICS
- FIGURE 7. GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
- FIGURE 8. GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 10. GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 12. GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
- FIGURE 14. GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.